Latest RSV infection Stories
Redundant targets extend coverage for detection of seasonal and emerging novel viruses SUNNYVALE, Calif., Nov.
Redundant targets extend coverage to provide detection of seasonal and emerging novel viruses SUNNYVALE, Calif., Sept.
Reportbuyer.com just published a new market research report:
ROCKVILLE, Md., Dec. 16, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S.
Researchers at National Jewish Health have discovered that a naturally occurring lipid in the lung can prevent RSV infection and inhibit spread of the virus after an infection is established.
Even mildly premature infants (gestational ages of 33 weeks through 36 weeks) have an increased risk of medically attended respiratory syncytial virus infection, which is the leading cause of lower respiratory tract infection in infants and young children and can lead to pneumonia in babies, according to a Kaiser Permanente Division of Research study.
- A serpent whose bite was fabled to produce intense thirst.